Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP Trial)
Recruiting in Palo Alto (17 mi)
+10 other locations
Overseen ByYuan-Kai Shi, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Betta Pharmaceuticals Co., Ltd.
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.
Eligibility Criteria
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: IcotinibExperimental Treatment1 Intervention
125 mg three times daily (375 mg per day) by mouth
Group II: PlaceboActive Control1 Intervention
1 tablet three times daily by mouth
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Loading ...
Who is running the clinical trial?
Betta Pharmaceuticals Co., Ltd.Lead Sponsor